1
|
Mao P, Xing L, He B, Deng T, Qin Y, Hu Y, An Y, Xue W. Antiviral activity evaluation and action mechanism of chalcone derivatives containing phenoxypyridine. Mol Divers 2025; 29:695-709. [PMID: 38584199 DOI: 10.1007/s11030-024-10843-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2024] [Accepted: 03/07/2024] [Indexed: 04/09/2024]
Abstract
In this paper, a series of phenoxypyridine-containing chalcone derivatives (L1-L28) were designed and synthesized, characterized on NMR and HRMS. Ningnanmycin (NNM) was used as a control agent. The results of the antiviral activity testing showed that the curative activity EC50 values of L1 and L4 against TMV were 140.5 and 90.7 μg/mL, respectively, which were superior to that of NNM (148.3 μg/mL). The EC50 values of 154.1, 102.6 and 140.0 μg/mL for the anti-TMV protective activities of L1, L4 and L15 were superior to that of NNM (188.2 μg/mL). The mechanism of action between L4 and NNM and tobacco mosaic virus capsid protein (TMV-CP) was preliminarily investigated. The results of microscale thermophoresis (MST) experiments showed that L4 had a strong binding affinity for TMV-CP with a dissociation constant Kd value of 0.00149 µM, which was better than that of NNM (2.73016 µM). The results of molecular docking experiments showed that L4 formed shorter hydrogen bonds with amino acid residues of TMV-CP than NNM and formed more amino acid residues than NNM, which indicated that L4 was more tightly bound to TMV-CP. This study suggested that phenoxypyridine-containing chalcone derivatives can be used as new anti-TMV drugs through further research and development.
Collapse
Affiliation(s)
- Piao Mao
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for R&D of Fine Chemicals, Guizhou University, Guiyang, 550025, China
| | - Li Xing
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for R&D of Fine Chemicals, Guizhou University, Guiyang, 550025, China
| | - Bangcan He
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for R&D of Fine Chemicals, Guizhou University, Guiyang, 550025, China
| | - Tianyu Deng
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for R&D of Fine Chemicals, Guizhou University, Guiyang, 550025, China
| | - Yishan Qin
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for R&D of Fine Chemicals, Guizhou University, Guiyang, 550025, China
| | - Yuzhi Hu
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for R&D of Fine Chemicals, Guizhou University, Guiyang, 550025, China
| | - Youshan An
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for R&D of Fine Chemicals, Guizhou University, Guiyang, 550025, China
| | - Wei Xue
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for R&D of Fine Chemicals, Guizhou University, Guiyang, 550025, China.
| |
Collapse
|
2
|
Michalkova R, Kello M, Cizmarikova M, Bardelcikova A, Mirossay L, Mojzis J. Chalcones and Gastrointestinal Cancers: Experimental Evidence. Int J Mol Sci 2023; 24:ijms24065964. [PMID: 36983038 PMCID: PMC10059739 DOI: 10.3390/ijms24065964] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Revised: 03/10/2023] [Accepted: 03/20/2023] [Indexed: 03/30/2023] Open
Abstract
Colorectal (CRC) and gastric cancers (GC) are the most common digestive tract cancers with a high incidence rate worldwide. The current treatment including surgery, chemotherapy or radiotherapy has several limitations such as drug toxicity, cancer recurrence or drug resistance and thus it is a great challenge to discover an effective and safe therapy for CRC and GC. In the last decade, numerous phytochemicals and their synthetic analogs have attracted attention due to their anticancer effect and low organ toxicity. Chalcones, plant-derived polyphenols, received marked attention due to their biological activities as well as for relatively easy structural manipulation and synthesis of new chalcone derivatives. In this study, we discuss the mechanisms by which chalcones in both in vitro and in vivo conditions suppress cancer cell proliferation or cancer formation.
Collapse
Affiliation(s)
- Radka Michalkova
- Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, 040 01 Košice, Slovakia
| | - Martin Kello
- Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, 040 01 Košice, Slovakia
| | - Martina Cizmarikova
- Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, 040 01 Košice, Slovakia
| | - Annamaria Bardelcikova
- Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, 040 01 Košice, Slovakia
| | - Ladislav Mirossay
- Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, 040 01 Košice, Slovakia
| | - Jan Mojzis
- Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, 040 01 Košice, Slovakia
| |
Collapse
|
3
|
Teli G, Chawla PA. Hybridization of Imidazole with Various Heterocycles in Targeting Cancer: A Decade's Work. ChemistrySelect 2021; 6:4803-4836. [DOI: 10.1002/slct.202101038] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Accepted: 05/05/2021] [Indexed: 01/04/2025]
Abstract
AbstractCancer is the world‘s biggest global health concern. The prevalence and mortality rates of cancer remain high despite significant progress in cancer therapy. The search for more effective, as well as less toxic treatment methods for cancer, is at the focus of current studies. Approximately 24.6 million people are suffering from cancer across the world as per the world health organization (WHO). In the year 2020, approximately 10 million deaths were reported due to cancer which has emerged as the second leading cause of mortality across the globe. Anticancer medicines have played a pivotal role in the medication of different types of cancers; however, they are associated with several side effects and relevance of drug resistance which evoke an immediate need for designing of new anticancer agents with multitargeted effect. Imidazole is a heterocyclic compound privileged with considerable anticancer activities and some imidazole derivatives have already got approval to treat cancer. Many hybrid molecules are available that play an important role in the treatment of cancer like chalcone, pyrazole, purine, triazine etc., and their pharmacophore provide the anticancer drug with low drug resistance and high efficacy, with low chances of toxicity and side effects. This review provides various approaches for the drug development of new safe and efficient antitumor agents imidazole hybrids with other heterocyclic moieties. An attempt has been made to advancement of the anticancer potential of the derivatives and hybrids of imidazole having intact or condensed imidazole moiety in the last decade along with the structure‐activity relationship studies, and mechanism of action.
Collapse
Affiliation(s)
- Ghanshyam Teli
- Department of Pharmaceutical Chemistry ISF College of Pharmacy Ghal Kalan G.T Road Punjab 142001 India
| | - Pooja A. Chawla
- Department of Pharmaceutical Chemistry ISF College of Pharmacy Ghal Kalan G.T Road Punjab 142001 India
| |
Collapse
|
4
|
Dandawate P, Ahmed K, Padhye S, Ahmad A, Biersack B. Anticancer Active Heterocyclic Chalcones: Recent Developments. Anticancer Agents Med Chem 2021; 21:558-566. [PMID: 32628595 DOI: 10.2174/1871520620666200705215722] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2019] [Revised: 02/27/2020] [Accepted: 04/07/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Chalcones are structurally simple compounds that are easily accessible by synthetic methods. Heterocyclic chalcones have gained the interest of scientists due to their diverse biological activities. The anti-tumor activities of heterocyclic chalcones are especially remarkable and the growing number of publications dealing with this topic warrants an up-to-date compilation. METHODS Search for antitumor active heterocyclic chalcones was carried out using Pubmed and Scifinder as common web-based literature searching tools. Pertinent and current literature was covered from 2015/2016 to 2019. Chemical structures, biological activities and modes of action of anti-tumor active heterocyclic chalcones are summarized. RESULTS Simply prepared chalcones have emerged over the last years with promising antitumor activities. Among them, there are a considerable number of tubulin polymerization inhibitors. But there are also new chalcones targeting special enzymes such as histone deacetylases or with DNA-binding properties. CONCLUSION This review provides a summary of recent heterocyclic chalcone derivatives with distinct antitumor activities.
Collapse
Affiliation(s)
- Prasad Dandawate
- Interdisciplinary Science and Technology Research Academy, Abeda Inamdar Senior College, University of Pune, 2390-B, K.B. Hidayatullah Road, Pune 411001, India
| | - Khursheed Ahmed
- Department of Chemistry, Abeda Inamdar Senior College, University of Pune, 2390-B, K.B. Hidayatullah Road, Pune 411001, India
| | - Subhash Padhye
- Interdisciplinary Science and Technology Research Academy, Abeda Inamdar Senior College, University of Pune, 2390-B, K.B. Hidayatullah Road, Pune 411001, India
| | - Aamir Ahmad
- University of Alabama at Birmingham, 9th Ave South, Birmingham AL 33294, United States
| | - Bernhard Biersack
- Organic Chemistry Laboratory, University of Bayreuth, Universitätsstrasse 30, 95440 Bayreuth, Germany
| |
Collapse
|
5
|
Alsafi MA, Hughes DL, Said MA. First COVID-19 molecular docking with a chalcone-based compound: synthesis, single-crystal structure and Hirshfeld surface analysis study. ACTA CRYSTALLOGRAPHICA SECTION C-STRUCTURAL CHEMISTRY 2020; 76:1043-1050. [PMID: 33273140 DOI: 10.1107/s2053229620014217] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Accepted: 10/25/2020] [Indexed: 12/14/2022]
Abstract
The first example of molecular docking of the SARS-CoV-2 main protease for COVID-19 [Mpro, Protein Data Bank (PDB) code 7BQY] by a chalcone-based ligand, namely, (E)-1-(2,4-dichlorophenyl)-3-[4-(morpholin-4-yl)phenyl]prop-2-en-1-one, C19H17Cl2NO2, I, is presented. Two-dimensional (2D) LIGPLOT representations calculated for the inhibitor N3, viz. N-{[(5-methylisoxazol-3-yl)carbonyl]alanyl}-L-valyl-N1-((1R,2Z)-4-(benzyloxy)-4-oxo-1-{[(3R)-2-oxopyrrolidin-3-yl]methyl}but-2-enyl)-L-leucinamide, and 7BQY are included for comparison with our chalcone-based complexes. The binding affinity of our chalcone ligand with 7BQY is -7.0 kcal mol-1, a high value which was attributed to the presence of a hydrogen bond, together with many hydrophobic interactions between the drug and the active amino acid residues of the receptor. Docking studies were also performed, employing rigid and flexible binding modes for the ligand. The superposition of N3 and the chalcone docked into the binding pocket of 7BQY is also presented. The synthesis, single-crystal structure, Hirshfeld surface analysis (HSA) and spectral characterization of heterocyclic chalcone-based compound I, are also presented. The molecules are stacked, with normal π-π interactions, in the crystal.
Collapse
Affiliation(s)
- Mona A Alsafi
- Chemistry Department, College of Science, Taibah University, PO Box 30002, Al-Madinah Al Munawarah, Code 1417, Saudi Arabia
| | - David L Hughes
- School of Chemistry, University of East Anglia, Norwich NR4 7TJ, England
| | - Musa A Said
- Chemistry Department, College of Science, Taibah University, PO Box 30002, Al-Madinah Al Munawarah, Code 1417, Saudi Arabia
| |
Collapse
|
6
|
Gao F, Huang G, Xiao J. Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure-activity relationship. Med Res Rev 2020; 40:2049-2084. [PMID: 32525247 DOI: 10.1002/med.21698] [Citation(s) in RCA: 75] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2020] [Revised: 05/19/2020] [Accepted: 05/24/2020] [Indexed: 12/14/2022]
Abstract
The continuous emergency of drug-resistant cancers and the low specificity of anticancer agents have been the major challenges in the control and treatment of cancer, making an urgent need to develop novel anticancer agents with high efficacy. Chalcones, precursors of flavonoids and isoflavonoids, exhibit structural heterogeneity and can act on various drug targets. Chalcones which demonstrated potential in vitro and in vivo activity against both drug-susceptible and drug-resistant cancers, are useful templates for the development of novel anticancer agents. Hybridization of chalcone moiety with other anticancer pharmacophores could provide the hybrids which have the potential to overcome drug resistance and improve the specificity, so it represents a promising strategy to develop novel anticancer agents. This review emphasizes the development, the mechanisms of action as well as structure-activity relationships of chalcone hybrids with potential therapeutic application for many cancers in recent 10 years.
Collapse
Affiliation(s)
- Feng Gao
- State Key Laboratory of Biobased Material and Green Papermaking (LBMP), Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.,Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China
| | - Gang Huang
- Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China
| | - Jiaqi Xiao
- State Key Laboratory of Biobased Material and Green Papermaking (LBMP), Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.,Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China
| |
Collapse
|
7
|
Antiproliferative Evaluation In Vitro of a New Chalcone Inducing Apoptosis by ROS Generation Against MGC-803 Cells. Pharm Chem J 2019. [DOI: 10.1007/s11094-019-02034-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
8
|
Fu DJ, Hou YH, Zhang SY, Zhang YB. Efficient click reaction towards novel sulfonamide hybrids by molecular hybridization strategy as antiproliferative agents. J CHEM SCI 2018. [DOI: 10.1007/s12039-017-1415-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Li N, Liu N, Tang S, Li DL, Zhang XJ. Synthesis and Antiproliferative Activity of Novel 1,2,3-Triazole-Sulfonamide Hybrids. JOURNAL OF CHEMICAL RESEARCH 2018. [DOI: 10.3184/174751918x15161933697853] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Nine novel 1-(4′-sulfamoylphenyl)-1,2,3-triazole derivatives bearing an N-heterocycle moiety were designed using a molecular hybridisation approach and synthesised by alkyne/azide click chemistry. Most of the synthesised compounds exhibited good to moderate antiproliferative activity (IC50 values 3.7 to 77.1 μM) against stomach, oesophagus and prostate cancer cell lines, but a compound containing an S-(2-pyridyl)thiomethyl moiety showed 10-fold greater activity against the stomach cell line than 5-fluorouracil. These results demonstrate that N-heterocycle-1,2,3-triazolylsulfonamides could be promising lead compounds to develop new antitumour drugs.
Collapse
Affiliation(s)
- Na Li
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P.R. China
- Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou 450052, P.R. China
| | - Nan Liu
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P.R. China
- Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou 450052, P.R. China
| | - Shu Tang
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P.R. China
- Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou 450052, P.R. China
| | - Duo-Lu Li
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P.R. China
- Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou 450052, P.R. China
| | - Xiao-Jian Zhang
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P.R. China
- Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou 450052, P.R. China
| |
Collapse
|
10
|
Fu DJ, Liu YC, Yang JJ, Zhang J, Xiong CD, Cao ZS, Yin XX, Wei W, Zhang YB. Design and Synthesis of Sulfonamide-1,2,3-Triazole Derivatives Bearing a Dithiocarbamate Moiety as Antiproliferative Agents. JOURNAL OF CHEMICAL RESEARCH 2017. [DOI: 10.3184/174751917x15027935057950] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A series of nine novel 1-(4′-sulfamoylphenyl)-1,2,3-triazole derivatives bearing a 4-dithiocarbamylmethyl moiety were designed using the molecular hybridisation approach and synthesised by alkyne/azide click chemistry. Most of the synthesised compounds exhibited moderate to good antiproliferative activity against oesophagus, gastric and prostate cancer cell lines, but a compound containing a 4-( t-butoxycarbonyl)piperazinylthiocarbonyl moiety showed the highest activity. Against a prostate cancer cell line, it had an IC50 value of 2.4 μM, about 10-fold more active than 5-flurouracil. This work shows that novel sulfonamide-1,2,3-triazole derivatives bearing a dithiocarbamate moiety linked to a 4-substituted piperazine are promising lead compounds for the development of antitumour agents.
Collapse
Affiliation(s)
- Dong-Jun Fu
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Ying-Chao Liu
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Jia-Jia Yang
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Ji Zhang
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Chao-Dong Xiong
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Zhu-Song Cao
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Xu-Xu Yin
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Wei Wei
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Yan-Bing Zhang
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| |
Collapse
|
11
|
Fu DJ, Zhao RH, Li JH, Yang JJ, Mao RW, Wu BW, Li P, Zi XL, Zhang QQ, Cai HJ, Zhang SY, Zhang YB, Liu HM. Molecular diversity of phenothiazines: design and synthesis of phenothiazine-dithiocarbamate hybrids as potential cell cycle blockers. Mol Divers 2017; 21:933-942. [PMID: 28785928 DOI: 10.1007/s11030-017-9773-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2017] [Accepted: 07/24/2017] [Indexed: 11/28/2022]
Abstract
Novel phenothiazine-dithiocarbamate analogues were designed by molecular hybridization strategy and synthesized and evaluated for their anticancer activity in vitro against three selected cancer cell lines (EC-109, MGC-803, and PC-3). The preliminary structure-activity relationship (SAR) for this phenothiazine-dithiocarbamate hybrids is explored. Among all analogues, 2-oxo-2-(10H-phenothiazin-10-yl)ethyl 4-ethylpiperazine-1-carbodithioate (8a) showed the most potent inhibitory activity with an [Formula: see text] value of [Formula: see text] against PC-3 cells. In addition, compound 8a could arrest the cell cycle at the G1 phase and regulate the expression of G1 checkpoint-related proteins, suggesting that phenothiazine-dithiocarbamate hybrids might be useful as cell cycle blockers.
Collapse
Affiliation(s)
- Dong-Jun Fu
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Ruo-Han Zhao
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Jia-Huan Li
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Jia-Jia Yang
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Ruo-Wang Mao
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Bo-Wen Wu
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Ping Li
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Xiao-Lin Zi
- Pathology and Laboratory Medicine, University of California, Irvine, Orange, CA, 92868, USA
| | - Qing-Qing Zhang
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Hui-Jie Cai
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Sai-Yang Zhang
- School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
| | - Yan-Bing Zhang
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China. .,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China. .,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China. .,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China.
| | - Hong-Min Liu
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China. .,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China. .,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China. .,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China.
| |
Collapse
|
12
|
Fu DJ, Zhang SY, Liu YC, Song J, Zhao RH, Mao RW, Liu HM, Zhang YB. Design, Synthesis and Antiproliferative Evaluation of 3-Aminopropyloxy Derivatives of Chalcone. JOURNAL OF CHEMICAL RESEARCH 2016. [DOI: 10.3184/174751916x14740434083371] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A series of 3-aminopropyloxy derivatives of chalcone were synthesised and evaluated for their antiproliferative activity against liver, gastric and neuroendocrine cancer cell lines. Most of the synthesised compounds exhibited moderate to good activity against all three cancer cell lines, but in particular, a 3-(pyrrolidin-1-yl)propyloxy chalcone containing a 3,4,5-trimethoxyphenyl group showed the highest antiproliferative activity with an IC50 value of 2.74 μM against liver cancer cells.
Collapse
Affiliation(s)
- Dong-Jun Fu
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Sai-Yang Zhang
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Ying-Chao Liu
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Jian Song
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Ruo-Han Zhao
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Ruo-Wang Mao
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Hong-Min Liu
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Yan-Bing Zhang
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| |
Collapse
|